依地酸二钠螯合治疗对既往心肌梗死合并糖尿病患者的影响:TACT2随机临床试验
TACT2是一项在美国和加拿大88个中心进行的2×2析因、双盲、安慰剂对照、多中心试验,纳入50岁及以上、糖尿病且心肌梗死至少6周前的患者,比较依地酸二钠(EDTA)螯合与安慰剂输注对心血管事件的影响。959名参与者中483人接受至少1次螯合输注、476人接受至少1次安慰剂输注,中位随访48个月。主要终点(全因死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定型心绞痛住院的复合终点)在螯合组172人(35.6%)与安慰剂组170人(35.7%)发生(调整HR 0.93,95%CI 0.76-1.16,P=.53),5年累积发生率分别为45.8%和46.5%。螯合有效降低血铅水平(中位数从基线9.03 μg/L降至第40次输注时3.46 μg/L,P<.001),但未减少心血管事件。
要点
- 糖尿病合并既往心肌梗死稳定患者中,EDTA螯合组主要终点事件35.6%(172/483)vs 安慰剂组35.7%(170/476),调整HR 0.93(95%CI 0.76-1.16),P=.53,无显著差异。
- 5年主要事件累积发生率螯合组45.8% vs 安慰剂组46.5%。
- 心血管死亡、心肌梗死或卒中:螯合组18.4%(89/483)vs 安慰剂组19.7%(94/476),调整HR 0.89(95%CI 0.66-1.19)。
- 全因死亡:螯合组17.4%(84/483)vs 安慰剂组17.6%(84/476),调整HR 0.96(95%CI 0.71-1.30)。
- 螯合有效降低血铅:中位数从基线9.03 μg/L降至第40次输注时3.46 μg/L(P<.001);安慰剂组从9.3 μg/L变为8.7 μg/L。
适用人群与场景
- 50岁及以上、患有糖尿病、且在招募前至少6周发生心肌梗死的患者,来自美国和加拿大88个中心。
- 本报告仅涉及螯合输注与安慰剂输注的比较,不涉及口服高剂量多种维生素和矿物质与口服安慰剂的比较。
处置流程与药物剂量
- 符合条件的参与者随机接受40次每周一次的EDTA基螯合溶液输注或匹配安慰剂输注,并随机接受每日两次口服高剂量多种维生素和矿物质补充剂或匹配安慰剂,持续60个月。
研究设计与关键结果
- 设计:2×2析因、双盲、安慰剂对照、多中心试验,88个中心,纳入959名参与者(中位年龄67岁,IQR 60-72岁;27%女性;78%白人、10%黑人、20%西班牙裔),483人接受至少1次螯合输注、476人接受至少1次安慰剂输注,中位随访48个月。
- 主要终点(全因死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定型心绞痛住院的复合终点):螯合组172人(35.6%)vs 安慰剂组170人(35.7%),调整HR 0.93(95%CI 0.76-1.16),P=.53;5年累积发生率螯合组45.8% vs 安慰剂组46.5%。
- 心血管死亡、心肌梗死或卒中:螯合组89人(18.4%)vs 安慰剂组94人(19.7%),调整HR 0.89(95%CI 0.66-1.19)。
- 全因死亡:螯合组84人(17.4%)vs 安慰剂组84人(17.6%),调整HR 0.96(95%CI 0.71-1.30)。
- 血铅中位数:螯合组从基线9.03 μg/L降至第40次输注时3.46 μg/L(P<.001);安慰剂组从9.3 μg/L变为8.7 μg/L。
证据类型、等级与局限
- 证据类型:随机对照试验(2×2析因、双盲、安慰剂对照、多中心)。
- 试验注册:ClinicalTrials.gov标识符NCT02733185。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:尽管有效降低血铅水平,EDTA螯合在合并糖尿病和心肌梗死病史的稳定冠状动脉疾病患者中未能有效减少心血管事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium (EDTA)-based chelation significantly reduced cardiovascular disease (CVD) events by 18% in 1708 patients with a prior myocardial infarction (MI).
OBJECTIVE: To replicate the finding of TACT in individuals with diabetes and previous MI.
DESIGN, SETTING, AND PARTICIPANTS: A 2 × 2 factorial, double-masked, placebo-controlled, multicenter trial at 88 sites in the US and Canada, involving participants who were 50 years or older, had diabetes, and had experienced an MI at least 6 weeks before recruitment compared the effect of EDTA-based chelation vs placebo infusions on CVD events and compared the effect of high doses of oral multivitamins and minerals with oral placebo. This article reports on the chelation vs placebo infusion comparisons.
INTERVENTIONS: Eligible participants were randomly assigned to 40 weekly infusions of an EDTA-based chelation solution or matching placebo and to twice daily oral, high-dose multivitamin and mineral supplements or matching placebo for 60 months. This article addresses the chelation study.
MAIN OUTCOMES AND MEASURES: The primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. Median follow-up was 48 months. Primary comparisons were made from patients who received at least 1 assigned infusion.
RESULTS: Of the 959 participants (median age, 67 years [IQR, 60-72 years]; 27% females; 78% White, 10% Black, and 20% Hispanic), 483 received at least 1 chelation infusion and 476 at least 1 placebo infusion. A primary end point event occurred in 172 participants (35.6%) in the chelation group and in 170 (35.7%) in the placebo group (adjusted hazard ratio [HR], 0.93; 95% CI, 0.76-1.16; P = .53). The 5-year primary event cumulative incidence rates were 45.8% for the chelation group and 46.5% for the placebo group. CV death, MI, or stroke events occurred in 89 participants (18.4%) in the chelation group and in 94 (19.7%) in the placebo group (adjusted HR, 0.89; 95% CI, 0.66-1.19). Death from any cause occurred in 84 participants (17.4%) in the chelation group and in 84 (17.6%) in the placebo group (adjusted HR, 0.96; 95% CI, 0.71-1.30). Chelation reduced median blood lead levels from 9.03 μg/L at baseline to 3.46 μg/L at infusion 40 (P < .001). Corresponding levels in the placebo group were 9.3 μg/L and 8.7 μg/L, respectively.
CONCLUSIONS AND RELEVANCE: Despite effectively reducing blood lead levels, EDTA chelation was not effective in reducing cardiovascular events in stable patients with coronary artery disease who have diabetes and a history of MI.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02733185.
参考来源
- Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. JAMA. 2024. PMID: 39141382. doi:10.1001/jama.2024.11463
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。